Author: Goodhue Meyer, Erin; Simmons, Graham; Grebe, Eduard; Gannett, Michael; Franz, Sergej; Darst, Orsolya; Di Germanio, Clara; Stone, Mars; Contestable, Paul; Prichard, Alicia; Reik, Rita; Vassallo, Ralph; Young, Pampee; Busch, Michael P.; Williamson, Phillip; Dumont, Larry J.
Title: Selecting COVIDâ€19 convalescent plasma for neutralizing antibody potency using a highâ€capacity SARSâ€CoVâ€2 antibody assay Cord-id: 9zs7g5jx Document date: 2021_2_18
ID: 9zs7g5jx
Snippet: BACKGROUND: Efficacy of COVIDâ€19 convalescent plasma (CCP) is hypothesized to be associated with the concentration of neutralizing antibodies (nAb) to SARSâ€CoVâ€2. High capacity serologic assays detecting binding antibodies (bAb) have been developed; nAb assays are not adaptable to highâ€throughput testing. We sought to determine the effectiveness of using surrogate bAb signalâ€toâ€cutoff ratios (S/Co) in predicting nAb titers using a pseudovirus reporter viral particle neutralization (R
Document: BACKGROUND: Efficacy of COVIDâ€19 convalescent plasma (CCP) is hypothesized to be associated with the concentration of neutralizing antibodies (nAb) to SARSâ€CoVâ€2. High capacity serologic assays detecting binding antibodies (bAb) have been developed; nAb assays are not adaptable to highâ€throughput testing. We sought to determine the effectiveness of using surrogate bAb signalâ€toâ€cutoff ratios (S/Co) in predicting nAb titers using a pseudovirus reporter viral particle neutralization (RVPN) assay. METHODS: CCP donor serum collected by three US blood collectors was tested with a bAb assay (Ortho Clinical Diagnostics VITROS Antiâ€SARSâ€CoVâ€2 Total, CoV2T) and a nAb RVPN assay. Prediction effectiveness of various CoV2T S/Co criteria was evaluated for RVPN nAb NT(50) titers using receiver operating characteristics. RESULTS: Seven hundred and fiftyâ€three CCPs were tested with median CoV2T S/Co and NT(50) of 71.2 of 527.5. Proportions of donors with NT(50) over target nAb titers were 86% ≥1:80, 76% ≥1:160, and 62% ≥1:320. Increasing CoV2T S/Co criterion reduced the sensitivity to predict NT(50) titers, while specificity to identify those below increased. As target NT50 titers increase, the CoV2T assay becomes less accurate as a predictor with a decline in positive predictive value and rise in negative predictive value. CONCLUSION: Selection of a clinically effective nAb titer will impact availability of CCP. Product release with CoV2T assay S/Co criterion must balance the risk of releasing products below target nAb titers with the cost of false negatives. A twoâ€step testing scheme may be optimal, with nAb testing on CoV2T samples with S/Cos below criterion.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date